Kodiak Sciences Inc.

Amunix Operating Inc.

Amunix Pharmaceuticals, Inc

Amgen Inc.

Bioverativ Therapeutics Inc.

Wayne To

Joshua A Silverman

Volker Schellenberger

Willem P Stemmer

Nathan C Geething

Benjamin Spink

Stephen A Charles

Chia-wei Wang

Didier G Benoit

Martin Sheringham Linsell

James Bradley Aggen

Jeffrey L Cleland

Daniel Victor Perlroth

D Victor Perlroth

Li Song

Lane A Clizbe

Lidia Mosyak

William Stuart Somers

Laura Lin

Tetsuya Ishino

Justin Cohen

Xiaojian Huang

Victor D Perlroth

Chia-Wei Wang

Didler Benoit

Chia-wel Wang

Linda J Zadik

Jeanne M Pratt

Nathan Carl Geething

Willem Peter Stemmer

Didier Benoit

Xiao Jian Huang

The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.

Factor VIII zwitterionic polymer conjugates

The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

Extended recombinant polypeptides and compositions comprising same

The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.

Multifunctional zwitterionic polymer conjugates

The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.

Dual PDGF/VEGF antagonists

The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.

Butyrylcholinesterase zwitterionic polymer conjugates

The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.

Coagulation factor IX compositions and methods of making and using same

The present invention relates to compositions comprising factor DC coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.

Growing community of inventors

Fremont, CA, United States of America

Wayne To